The Latin America, Middle East and Africa Cat Vaccine Market is projected to witness market growth of 11.7% CAGR during the forecast period (2024-2031).
The Brazil market dominated the LAMEA Cat Vaccine Market by Country in 2023, and is forecast to continue being a dominant market till 2031; thereby, achieving a market value of $54 million by 2031. The Argentina market is capturing a CAGR of 12.6% during (2024 - 2031). Additionally, The UAE market would register a CAGR of 10.9% during (2024 - 2031).
The development of recombinant DNA technology has enabled the production of vaccines that can target specific pathogens with greater precision. This method reduces the risk of adverse reactions and enhances the immune response in cats. As a result, newer vaccines can offer longer-lasting protection against diseases such as feline leukemia virus (FeLV), feline immunodeficiency virus (FIV), and rabies, contributing to cats' overall health and longevity.
Despite the positive trends, the market also faces several challenges. One of the most significant barriers is the high cost of vaccines, which can deter pet owners, especially those with multiple cats or limited financial resources. Even with the availability of pet insurance, the upfront costs associated with comprehensive vaccination schedules can be prohibitive for some. This financial burden can lower vaccination rates, leaving cats vulnerable to preventable diseases.
The South African Veterinary Association (SAVA) has actively promoted the importance of regular vaccinations through public health initiatives and educational campaigns. The Department of Agriculture, Forestry, and Fisheries (DAFF) supports these efforts by ensuring that veterinary services are accessible and affordable. The demand for cat vaccines has been driven by enhanced public awareness and the increasing disposable income of pet owners, who are more inclined to invest in preventive healthcare for their animals. Thus, the LAMEA cat vaccine market has growth potential fueled by rising pet ownership and increasing awareness of animal welfare.
The Brazil market dominated the LAMEA Cat Vaccine Market by Country in 2023, and is forecast to continue being a dominant market till 2031; thereby, achieving a market value of $54 million by 2031. The Argentina market is capturing a CAGR of 12.6% during (2024 - 2031). Additionally, The UAE market would register a CAGR of 10.9% during (2024 - 2031).
The development of recombinant DNA technology has enabled the production of vaccines that can target specific pathogens with greater precision. This method reduces the risk of adverse reactions and enhances the immune response in cats. As a result, newer vaccines can offer longer-lasting protection against diseases such as feline leukemia virus (FeLV), feline immunodeficiency virus (FIV), and rabies, contributing to cats' overall health and longevity.
Despite the positive trends, the market also faces several challenges. One of the most significant barriers is the high cost of vaccines, which can deter pet owners, especially those with multiple cats or limited financial resources. Even with the availability of pet insurance, the upfront costs associated with comprehensive vaccination schedules can be prohibitive for some. This financial burden can lower vaccination rates, leaving cats vulnerable to preventable diseases.
The South African Veterinary Association (SAVA) has actively promoted the importance of regular vaccinations through public health initiatives and educational campaigns. The Department of Agriculture, Forestry, and Fisheries (DAFF) supports these efforts by ensuring that veterinary services are accessible and affordable. The demand for cat vaccines has been driven by enhanced public awareness and the increasing disposable income of pet owners, who are more inclined to invest in preventive healthcare for their animals. Thus, the LAMEA cat vaccine market has growth potential fueled by rising pet ownership and increasing awareness of animal welfare.
List of Key Companies Profiled
- Zoetis, Inc.
- Elanco Animal Health, Inc.
- Merck & Co., Inc.
- Boehringer Ingelheim International GmbH
- Covetrus, Inc. (Clayton, Dubilier & Rice, LLC)
- Virbac
- Heska Corporation (Antech Diagnostics, Inc)
- Ceva Sante Animale
- Bioveta, a.s.
Market Report Segmentation
By Component- Combined Vaccines
- Mono Vaccines
- Injectables
- Intranasal
- Oral
- 1 Year
- 3 Year
- Others
- Feline Respiratory Diseases
- Feline Rabies
- Feline Panleukopenia (Feline Distemper)
- Feline Leukemia
- Others
- Modified/Attenuated Live
- Inactivated (Killed)
- Others
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. LAMEA Cat Vaccine Market by Component
Chapter 6. LAMEA Cat Vaccine Market by Route of Administration
Chapter 7. LAMEA Cat Vaccine Market by Duration of Immunity
Chapter 8. LAMEA Cat Vaccine Market by Disease Type
Chapter 9. LAMEA Cat Vaccine Market by Type
Chapter 10. LAMEA Cat Vaccine Market by Country
Chapter 11. Company Profiles
Companies Mentioned
- Zoetis, Inc.
- Elanco Animal Health, Inc.
- Merck & Co., Inc.
- Boehringer Ingelheim International GmbH
- Covetrus, Inc. (Clayton, Dubilier & Rice, LLC)
- Virbac
- Heska Corporation (Antech Diagnostics, Inc)
- Ceva Sante Animale
- Bioveta, a.s.
Methodology
LOADING...
